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Chagas disease (CD) is one of the most neglected public health problems in the 
Americas, where <1% of the estimated 6 million people with the infection have been 
diagnosed and treated. The goal of treatment is to eliminate the parasite, decrease the 
probability of cardiomyopathy and other complications during the chronic stage of 
infection, and interrupt the cycle of disease transmission by preventing congenital 
infection. Currently, only benznidazole (BZN) and nifurtimox are recognized by the 
World Health Organization as effective drugs for treatment of CD. In this paper, we 
provide an overview of the clinical pharmacology of BZN. 
Areas covered 
This review covers the historical background, chemistry, mechanism of action, 
pharmacokinetics, preclinical research, resistance, clinical research, toxicology, adverse 
effects, and current regulatory status of BZN.    
Expert commentary 
Ongoing investigations aim to optimize BZN therapy by adjusting the current standard 
regimen or by combining BZN with new chemical entities. These studies are assessing 
alternatives that improve safety while maintaining or increasing the efficacy of BZN. 
Timely diagnosis and antitrypanosomal treatment are critical components of programs 
to eliminate CD as a public health problem, and can dramatically reduce the heavy 
burden of morbidity and mortality caused by the disease.  
 













Chagas disease (CD) is one of the most neglected public health problems in the 
Americas, where <1% of the estimated 6 million cases (including >300,000 in the 
United States)[1,2] have been diagnosed and treated. CD is also a significant public 
health challenge in Europe, where <10% of the estimated 68,000-122,000 cases have 
been diagnosed or treated.[3] Globally, CD creates an annual burden exceeding 800,000 
disability adjusted life years and $600,000,000 in healthcare costs.[4]  
Caused by the protozoan Trypanosoma cruzi, CD is mainly spread by triatomine bugs 
and by mother-to-child transmission. The parasite is also transmitted through blood 
transfusions, organ donations, laboratory accidents, needle sharing among drug users, or 
orally through food and drink contaminated with triatomines or their faeces.[5]  
CD begins with an acute phase with a lack of defining features; it is often asymptomatic 
or resembles a common viral illness, although more serious outcomes such as 
myocarditis or meningoencephalitis are possible. During this time, T. cruzi 
trypomastigotes are directly observed in the bloodstream. After this comes an 
indeterminate chronic phase during which T. cruzi  lodges in organ tissue in amastigote 
form,  inducing a specific  immune response. While most remain asymptomatic, 30-40% 
of patients progress to an advanced disease stage, usually years to decades after the 
initial infection. The advanced chronic phase frequently involves damage to the heart’s 
conduction system and myocardium, which can result in heart failure and sudden death. 
In the Americas, myocarditis secondary to CD is the most common form of 
nonischemic cardiomyopathy.[6] In other cases, CD produces gastrointestinal 
complications (especially megaesophagus and megacolon), or disorders of the central or 
peripheral nervous system, particularly in immunocompromised patients.  Benznidazole 
(BZN) and nifurtimox (NFX) are the only drugs with proven effectiveness against T. 
cruzi. Both drugs are over 40 years old; NFX, developed by Bayer, was registered in 
1967 and Roche registered benznidazole in 1971. The goal of etiological treatment of 
CD with BZN or NFX is to eliminate the parasite, thereby improving clinical outcomes 
in the patient and interrupting the cycle of disease transmission by blocking the 
congenital route of infection.[7]  
Treatment recommendations have historically varied depending on disease phase and 











1960’s, investigators affirmed that NFX and BZN were effective for treating both acute 
and chronic CD.[8] However, in 1983 an expert panel recommended against treatment 
in the chronic phase, based on the limited evidence of efficacy available and the belief 
that chronic CD symptoms were the product of an intense immune response unrelated to 
parasite presence, rendering etiological treatment fruitless.[9] Subsequently, while acute 
or congenital cases and children were routinely treated, adults in the chronic phase (the 
vast majority of CD patients) could only hope for palliative care. Nonetheless, by the 
late 2000’s, evidence mounted indicating that parasite persistence acted as a trigger for 
chronic CD pathology.[10] Key studies demonstrated that etiological treatment 
significantly improved clinical outcomes in adults with chronic CD.[11-13] The 
indication for supporting treatment during the chronic phase of infection was finally 
reinstated, and the World Health Organization (WHO), Centers for Disease Control 
(CDC), Médecins sans Frontières/Doctors without Borders (MSF), and other health 
organizations, as well as national guidelines in endemic and non-endemic countries, 
recommended offering treatment to adults during the chronic indeterminate phase. 
Currently, etiological treatment of CD using BZN and nifurtimox is indicated for: a) the 
acute phase, including neonates or infants with congenital transmission; b) reactivation 
of infection due to immune suppression; c) the chronic phase in patients up to 18 years 
old, and d) women of childbearing age with T. cruzi infection (contraception is 
recommended during treatment). Treatment may also be considered as a prophylactic 
measure for patients who are about to receive immunosuppressive therapy; however, 
there is not a complete consensus among experts on this recommendation, as some 
prefer to monitor patients closely and only treat in the event of reactivation. 
There is agreement in international clinical guidelines that antiparasitic treatment should 
be offered to adults aged 19–50 years without advanced Chagas heart disease, and is 
optional for those older than 50.[14-17] Nonetheless, such treatment has not been 
widely implemented due to a host of barriers, including: 1) low provider awareness of 
CD and its treatment options, 2) concerns about side effects, 3) low access to healthcare 
for many patients with CD, 4) lack of a straightforward test of cure, and 5) regulatory 
barriers.[18-20] 
BZN is the most commonly used treatment for CD. The recommended treatment course 
is 5-7 mg/kg orally, divided into two or three daily doses for 60 days for adults, and 5-











12.[16] In this article, we provide an overview of the clinical and pharmacological 
properties of benznidazole. 
 
2. Introduction to Benznidazole (BZN) 
2.1. Historical Background 
BZN is a member of a large group of nitroheterocyclic compounds, which comprises 
molecules containing one or more nitro-groups linked to an aromatic ring.[21] 
Nitroheterocyclic compounds have a long history of human and veterinary use as 
antimicrobial and antiparasitic agents. Although the particular use of nitrofuran 
derivatives was discontinued in some parts of the world due to mutagenic potential, 
there has been a resurgence of R&D on nitroaromatic compounds as potential 
therapeutic candidates.[21-25] 
The identification in the 1950’s of nitrofurazone as an active compound against 
Trypanosoma species pointed to the potential of nitroheterocyclic compounds as 
antiparasitic agents for treating human African trypanosomiasis and CD.[23] Although 
nitrofurazone did not provide optimal efficacy and safety in humans, this earlier 
investigation led to the identification and development of BZN and NFX, both 
nitroaromatic compounds, for treatment of CD.[23-27] 
2.2 Chemistry 
BZN (Box 1) is a 2-nitroimidazole derivative whose chemical name is N-benzyl-2-(2-
nitro-1H-imidazol-1-yl) acetamide. Its molecular formula is C12H12N4O3, with a 
molecular weight of 260.25 g/mol. BZN is provided in different tablet sizes containing 
the active pharmaceutical ingredient, formulated with common excipients approved by 
regulatory agencies for human drug products. 
Figure 1. Drug summary. 













Molecular formula C12H12N4O3 
Molecular weight 260.25 g/mol 
Mechanism of action After activation by trypanosomal 
nitroreductases, the reactive metabolites 
formed interact with several 
biomolecules leading to the killing of 
parasites 
Manufacturers LAFEPE, ELEA, CHEMO RESEARCH 
US FDA approval August 29th, 2017 
Indication  Acute and chronic phase with some 
limitations 
Treatment course  60 days 
Route of administration Oral 
Dosage form Tablets – 100, 50, 12.5 mg  
Breastfeeding women  Not recommended; however, 
preliminary research suggests there is no 
risk to infants.[28] 
 
2.3. Mechanism of action 
BZN is a prodrug that exerts trypanocidal activity after activation to produce reactive 
metabolites.[24,25,29,30] In T. cruzi, BZN is enzymatically activated by trypanosomal 
type I nitroreductases (NTR), a class of oxygen-insensitive enzymes present in several 
protozoan parasites, for which there is no mammalian homologue.[24] 
In a series of reactions (see Patterson 2014 for detailed information), NADH-dependent 
type I NTRs catalyze the reduction of the 2-nitroimidazole motif to a hydroxylamine, 
via a nitroso intermediate, in a two-step/two-electron transfer reaction.[24,25] This 
hydroxylamine is subsequently converted, via a series of non-enzymatic 
transformations, until the release of dialdehyde glyoxal, a highly reactive metabolite 
capable of forming adducts with proteins, DNA/RNA, and small molecules such as 
glutathione. These reactive metabolites are toxic, resulting in a rapid and localized 











However, glyoxal production is not likely to be the sole cytotoxic mechanism for BZN. 
A recent study, employing metabolomics approaches, showed that BZN is extensively 
metabolized to a number of reactive metabolites in epimastigotes, but the authors were 
unable to detect glyoxal and related adducts.[31] Instead, they proposed that covalent 
binding of multiple reactive metabolites to low molecular weight thiols (important 
within glutathione and trypanothione pathways) is BZN’s primary mode of action 
against T. cruzi.[31] Other studies suggest BZN possesses immunomodulatory effects in 
vitro, in vivo, and ex vivo, which could play an important role in CD pathogenesis in 
humans.[32,33] 
2.4. Pharmacokinetics 
The non-clinical pharmacokinetics (PK) of BZN have been evaluated in multiple 
studies.[34-37] Overall findings suggest BZN is almost fully bioavailable when 
administered orally, with a plasma half-life of 2-2.5 hours, and plasma protein binding 
approximating 50% across species. After absorption, BZN distributes widely to tissues, 
including placental and fetal tissue, at levels similar to that in circulating blood. The 
metabolic and excretion pathways for this drug h ve not yet been fully elucidated 
(although nitroreductases are involved in the conversion of the nitroimidazole motif), 
but studies demonstrate minimal metabolism in hepatic microsomes and hepatocytes of 
different species, and no human-specific metabolites.[34,37] No inhibition or induction 
of CYP450 enzymes at clinically relevant concentrations were detected during in vitro 
studies using human hepatocytes, although BZN was shown to be a substrate and to 
increase the expression of glycoprotein-P (efflux pump),[37,38] and to inhibit the OAT3 
receptor (with possible implications for drug-drug interactions).[37]  
 
2.5. Preclinical research 
Preclinical research has yielded further insight on the susceptibility of different T. cruzi 
strains to BZN. Notable studies are briefly described below. 
In vitro studies 
In vitro activity of BZN has been evaluated against >50 laboratory strains and clinical 
isolates of T. cruzi belonging to different discrete typing units (DTUs).[37,39-44] A 











including different stages of the parasite, axenic or intracellular parasite cultures, 
varying duration of treatment, and different endpoints to measure activity. Limited 
interlaboratory comparability and lack of understanding of the clinical relevance of in 
vitro sensitivity testing are major drawbacks for CD drug discovery. Improved and 
evolving experimental designs are paramount to answering relevant questions and to 
helping translate experimental data into knowledge.[45] 
Overall in vitro data suggest susceptibility of different strains to BZN fluctuates, but the 
50% inhibitory concentration (IC50) values are always ≤19.5μg/mL (75μM) and vary 
within a factor of ten-fold within the same assay. Activity against different forms of the 
parasite (epimastigotes, trypomastigotes, or amastigotes) also appears to vary within a 
relatively small range.[37,42,44] Additionally, time-kill studies indicate that BZN’s 
trypanocidal effect is both time- and concentration dependent.[39,42,44] Using multiple 
strains and a high-throughput screening platform, Moraes et al. demonstrated that BZN 
has a rapid trypanocidal effect and reaches 100% parasite clearance against multiple 
divergent T. cruzi genotypes,41 a rate superior to that for ergosterol biosynthesis 
inhibitors, for example. 
In vivo studies 
Several in vivo models mimic different aspects of human CD, and various formats have 
been widely used by the scientific community. However, current animal models have 
limitations, including variability of pathogen/host interactions, spontaneous clearance of 
parasites, and difficulties in identifying sterile parasitological cure and/or measuring 
drug treatment in real time, and thus have limited predictive value for development of 
new drug candidates.[46] 
In vivo activity of BZN has been evaluated, in both acute and chronic stages, against 
approximately 64 strains/clones infecting (most frequently) mice, rabbits, and 
dogs.[37,39,40,42,47-52] Findings in animals suggest that BZN treatment is beneficial 
in both CD stages, but more efficacious in acute models of T. cruzi infection. BZN 
improves survival, decreases parasitaemia in blood and reservoir tissues including the 
heart and gastrointestinal tract, eventually achieving full parasite clearance, and reduces 
the immunological response to parasite antigens. In animal models, the prevention of 











In dogs, an important reservoir of T. cruzi parasites providing an animal model where 
clinical findings and immunopathogenic mechanisms are similar to those reported in 
humans with CD, BZN was effective in reducing parasitic load during the acute or 
chronic phase of infection. However, while BZN effectively reduced systolic cardiac 
function alterations, it did not prevent development of cardiomyopathy in the chronic 
phase.[51,53-55] 
Intriguingly, two recent studies suggested BZN more readily cures chronic infections in 
mice, challenging the convention that it is more efficacious during the acute 
stage.[56,57] The investigators used a highly sensitive bioluminescence imaging system 
coupled with cyclophosphamide-mediated immunosuppression (to enhance the 
reactivation of any residual infection) for systematic and comparative studies of drug 
efficacy in vivo and ex vivo. Daily treatment of chronically infected mice with 100 
mg/kg of BZN for 5, 10, or 20 days resulted in sterile cure. However, mice in the acute 
stage with the same treatment regimen for 5 or 10 days were not cured.[57] These 
findings could have major implications for new research directions. 
Safety, Pharmacology and Toxicology 
Non-clinical pharmacological and toxicological profiling of BZN has yielded multiple 
clinically relevant findings. Potential concerns include carcinogenicity, teratogenicity, 
effects on male fertility and female pregnancy, and in vitro and in vivo genotoxicity 
(positive mutagenicity and clastogenicity).[35,37,48,58,59] These results align with 
findings for other nitroimidazolic drugs used in the clinic, such as metronidazole. These 
toxic effects may be partially driven by reactive oxygen species arising from the 
reduction of the nitro group to an amino group by type II NTRs (oxygen-sensitive), 
which are present in mammalian organisms.[24,31,37]  
2.6. Resistance 
Several in vitro and in vivo studies suggest, via a comparison of parasite growth kinetics 
and cure rates in animal models, evaluation of shifts in IC50 values, and molecular 
approaches, that there is the potential for development of resistance to BZN .[37,60-63] 
However, while there is clear evidence of resistance in T. cruzi under multiple 
experimental conditions, a direct link between in vitro / in vivo susceptibility and the 











The mechanism of generation of resistance is likely to be multifactorial, involving 
higher activity of efflux pumps, and mutation and/or modulation of parasite gene 
expression . [35,37,60-63] A recent whole genome sequencing study showed that 
mutagenic effects of BZN-reactive metabolites, combined with deficiencies in DNA 
repair mechanisms, could generate early-stage, extensive alterations in the T. cruzi 
genome, leading to the development of BZN resistance and other phenotypic 
changes.[64] 
 
3. Clinical Research on Benznidazole 
Clinical R&D for benznidazole (and CD more generally) has been hampered by a lack 
of investment. Only one large-scale, multicentric, randomized trial has taken place in 
the last half century.[65] Another challenge involves the difficulty of measuring 
treatment success during the chronic phase. Detection of the parasite (or parasite DNA) 
is a probable indication of treatment failure. Early studies relied on xenodiagnosis, 
while more recently polymerase chain reaction (PCR) has been employed. Negative 
serology is an effective proxy for parasitological cure in acute, congenital, and early 
chronic cases. However, in adult patients with chronic CD, it can take over 20 years 
following treatment to revert to negative serology.[12] There is an urgent need for 
development of a reliable test of cure to advance research and facilitate treatment.  
 
Phase I studies 
In the 1970’s,  multiple case series supported the safety of BZN.[66-68] 
Raaflaub et al published the first study of BZN resembling a modern Phase I study.[69] 
In this Roche-sponsored study, BZN’s PK were evaluated in six healthy adult female 
volunteers aged 22-24 years old, after administration of a single 100 mg BZN dose. The 
investigators reported quick absorption of the drug (Tmax 3hrs), good distribution to 
tissues (volume of distribution 560 ml/kg) and moderately slow elimination (estimated 
average half-life of 12 hrs). No significant adverse events were observed. Despite the 
small sample, the investigators decided to proceed with a repeated-dose study 
(comparable to a modern phase II study) of 14 patients with chronic CD, in which no 











Perhaps the most complete Phase I research to date assessed BZN for treatment of 
central nervous system cancers in adults (as an adjuvant therapy for CCNU).[71,72] 
These studies, which enrolled a higher number of patients and exposed them to 
incremental BZN doses (up to 40 mg/kg, over four times higher than the doses for CD), 
yielded PK and safety results compatible with prior research.[69,70] Through biopsies, 
the investigators confirmed high tissue penetration of BZN, even in the central nervous 
system (CNS), an observation that later became relevant when treating reactivated CNS 
T. cruzi infections in immunosuppressed patients.[73] 
A recent Phase I, open-label, nonrandomized pharmacokinetic study with eight healthy 
adult volunteers investigated the PK of a single 100 mg dose of BZN and used the 
calculated non-compartmental PK parameters to simulate two multiple-dose 
administration regimens: 100 mg administered every 8 hours and 150 mg administered 
every 12 hours. Observed PK parameters were similar to those in other studies, but the 
authors concluded that both simulated regimens reached steady-state concentrations 
above the minimum experimental therapeutic dose. Men had lower median Cmax and 
higher median volume of distribution than women, but the limited number of 
individuals (N=4 per group) precludes definitive conclusions on the influence of sex on 
BZN PK.[74] The BZN label mentions that food does not seem to affect absorption of 
the medication, according to comparative bioavailability studies performed for 
registration of the product in the USA.[37] 
Studies in children and lactating women have also been conducted. Early paediatric 
studies highlighted BZN’s efficacy for treating CD, measured by persistent decreases in 
conventional antibody titers and seroreversion, compared to placebo, and noted a low 
frequency of adv rse events in children.[75,76] Similarly, a case series and two 
prospective population pharmacokinetics studies confirmed BZN’s efficacy in infants 
and children using quantitative PCR (qPCR), which became universally negative after 
treatment, and conventional serological tests.[77,78] The frequency of adverse events 
was low, significantly below that reported for adults. Both studies showed a 
significantly shorter half-life due to higher clearance rates for BZN in younger children 
and infants, which was inversely proportional to body size. A systematic literature 
review with a Bayesian meta-analysis of basic pharmacokinetic properties of BZN 
showed consistency across studies; the authors provided improved estimates of the 











in adults. AUC and Cmax were 51.31 mg · h/liter (95% credible interval [CrI], 45.01-
60.28 mg · h/liter) and 2.19 mg/liter (95% CrI, 2.06, -2.33 mg/liter).[79]  
Phase II studies 
In an early study of 73 patients with acute CD treated with BZN, the cure rate 
(measured by xenodiagnosis) reached 88%. Additionally, three dosing regimens were 
tested in 33 patients with chronic infection: a) 7 to 10 mg/kg/day for 60 days; b) 7 to 10 
mg/kg/day for 30 days; and 4 to 5 mg/kg/day for 30 days. There were no statistical 
differences between treatment efficacy, with >90% of xenodiagnoses negative, but the 
higher dose produced more side effects.[8] 
After decades of limited research, several recent studies have evaluated the safety and 
efficacy of BZN at lower, shorter, and/or intermittent dosing regimens, both as a 
monotherapy and in combination with other compounds.  
 
E1224 
The E1224 study, sponsored by the Drugs for Neglected Diseases initiative (DNDi) was 
a proof-of-concept, double-blinded, randomized Phase II clinical trial.[80] E1224 
(ravuconazole), developed by Eisai, Ltd., had demonstrated promising activity against 
T. cruzi in animal models.[54] Adult Bolivian patients (n=231) with confirmed chronic 
indeterminate CD were randomly assigned to five oral treatment groups: high-dose 
E1224 (8 weeks, total dose 4000 mg), low-dose E1224 (8 weeks, 2000 mg), short-dose 
E1224 (4 weeks E1224 + 4 weeks placebo, 2400 mg), BZN standard dose (60 days, 5 
mg/kg per day), or placebo (8 weeks, E1224-matched tablets). The primary endpoint 
was parasite clearance. Although E1224 initially proved capable of eliminating the 
parasite, the effect was not sustained at 12-months follow-up. However, 82% of patients 
treated with BZN had negative PCR results at 12 months follow-up, underscoring the 
drug’s efficacy.   The study served as a springboard for a currently ongoing DNDi-
supported study of BZN at alternative dosing regimens and in combination with 
E1224.[81]  
CHAGASAZOL 
Undertaken in Barcelona, Spain, CHAGASAZOL was a multicenter, randomized, open-











mg/12 hours for 60 days), compared to BZN (5 mg/kg/day for 60 days) in 78 chronic 
CD patients.[82] During follow-up, a greater proportion of patients treated with 
posaconazole (81-92% vs. 38% for BZN) had treatment failure, as measured by positive 
real-time PCR for T. cruzi in peripheral blood.  
STOP Chagas 
STOP CHAGAS assessed posaconazole and BZN as monotherapies, posaconazole in 
combination with BZN, and placebo in a sample of 120 subjects from four Latin 
American countries and Spain.[83] After 180 days of follow-up, only 13.3% of patients 
treated with posaconazole had negative PCR results, compared with 10% in the placebo 
arm. However, 80% of patients in the BZN+posaconazole group and 86.7% of patients 
who received BZN as a monotherapy had negative results. Like E1224, posaconazole 
showed some effectiveness during treatment, but negativization was not sustained in the 
follow-up period.  
Intermittent Regimen 
A recent observational study assessed an intermittent dosage scheme of BZN at 5 
mg/kg/day in two daily doses every 5 days for a total of 60 days. One patient showed 
detectable PCR at the end of treatment (1/17), corresponding to 6% treatment failure, 
compared with 11/17 (65%) patients pretreatment (P = 0.01). Adverse effects were 
present in 10/20 (50%) patients, but in only one case was treatment suspended.[84]  
Ongoing studies 
The aforementioned studies supported the effectiveness of BZN for eliminating the 
parasite during the chronic phase of CD, whereas E1224 and posaconazole 
demonstrated temporary but unsustained parasite-clearing potential. Consequently, new 
research is focusing on improved regimens of benznidazole, either as a monotherapy or 
in combination with E1224. These studies aim to ascertain whether the side effect 
profile might be improved while maintaining or even improving the efficacy of the 
current standard dosing regimen. 
Currently, two new proof-of-concept studies are underway. BENDITA (BEnznidazole 
New Doses Improved Treatment and Associations) is a phase II randomized, multi-











and in combination with E1224, compared to placebo, in patients with chronic CD.  
(ClinicalTrials.gov Identifier: NCT03378661). MULTIBENZ (Evaluation of Different 
Benznidazole Regimens for the Treatment of Chronic Chagas Disease) (BERENICE 
Project, ClinicalTrials.gov Identifier: NCT03191162) is testing a modified regimen of 
BZN for treatment of CD in the chronic phase compared to the standard scheme.[74]  
Phase III studies  
Phase III studies have evaluated BZN’s efficacy in eliminating the parasite and 
improving clinical outcomes. Antiparasitic effects of treatment are measured through 
detection of antibodies, parasites, and/or parasite DNA. Success of treatment is gauged 
by negative serology, while therapeutic failure is demonstrated by parasite detection. 
However, the reliability of these indicators hinges on: (a) the age of the patient at the 
moment he/she received the treatment; (b) the time elapsed between treatment and 
follow-up; and (c) the region where the patient was infected.[7]   
Reversion to negative serology is much easier to demonstrate in patients who were more 
recently infected. Consequently, the efficacy of BZN for treatment of patients in the 
acute phase due to vector transmission or congenital infection has been clearly shown in 
several observational studies with a cure rate of consistently over 80%.[67,85-89]  
Studies assessing the efficacy of BZN in chronically infected patients are summarized in 
Table 1. BZN efficacy in asymptomatic chronically infected children was demonstrated 
by two double-blinded, placebo-controlled trials in the 1990’s. Cure rates, defined as 
conversion from positive to negative serology 3-4 years after treatment, were 
approximately 60%.[75,76] In one study, at 48 months follow-up, 51% of  the placebo 
group had a positive xenodiagnosis compared to 4.1% of patients treated with BZN.[76] 
These studies supported policy change in endemic countries toward treating children 
with indeterminate chronic CD. 
As patient age and length of infection increase, the time needed for seroreversion also 
increases. In one study, which defined treatment success as reversion to negative 
serology and treatment failure as a positive parasitological (xenodiagnosis) or molecular 
test (PCR), the rate of negativization was higher in children and adolescents than in 
adult patients (28.3 vs 11.1%) in short term (<10 years) follow-up, and substantially 











of treatment failure were much lower for children/adolescents compared to adults in 
both long and short-term follow-up. Timely treatment of children during the early 
chronic phase can yield a cure rate of up to 80%,[90,91] with higher rates observed 
when long-term follow-up is performed (Figure2B). Furthermore, following treatment, 
antibody titer levels decrease much more quickly in children than in adults, even if they 
do not cross the cut-off to become non-reactive. A marked decrease in antibody titers in 
children is apparent three months after treatment by enzyme linked immunosorbent 
assay or immunofluorescence assay, and six months after treatment using indirect 
haemagglutination assay.[75,76]  
Despite the difficulty of measuring cure in chronically infected adults, most 
observational studies have demonstrated improved clinical outcomes in patients who are 
treated with BZN, compared to untreated patients (Table 2). In a sample of 566 
Argentinian patients, only 4% of the treated group experienced progression of heart 
disease compared to 14% in the untreated group.[11] Other studies in different settings 
have described similar results, with reduction in disease progression of up to 
75%.[12,92-96] However, other researchers did not observe differences between treated 
and untreated patients.[97,98] 
Some research indicates treatment with BZN eliminates maternal transmission of CD. 
In a multicenter, observational study of a cohort of mothers and children, trypanocidal 
treatment of women with CD proved effective at preventing congenital transmission of 
T. cruzi and halting disease progression.[93] These results are consistent with other 
observational studies in which no congenital infection was detected in children born to 
T. cruzi-positive mothers who were treated before pregnancy.[99-102] 
A major randomized trial sought to determine whether treatment with BZN could 
improve outcomes for patients who had already developed heart disease.[65] The 
BENEFIT trial (Benznidazole Evaluation for Interrupting Trypanosomiasis), was a 
multicenter, double-blind, placebo-controlled trial of trypanocidal treatment of BZN in 
2,854 patients with chronic CD-related cardiomyopathy, conducted in 54 study centers 
in Argentina, Bolivia, Brazil, Colombia, and El Salvador. BZN was administered at a 
fixed daily dose of 300 mg for 40–80 days; the time period was adjusted according to 
body weight. The primary outcome was death, implantation of a pacemaker or 
defibrillator, transplant, heart failure, or other major cardiac event. Rates of conversion 











a significant difference in primary outcome between the placebo and BZN-treated 
group, even though parasite clearance was higher in the latter (66.2 vs. 33.5%). The 
mean patient age in the trial was 55, and most patients had New York Heart Association 
class I or II heart failure.  
TRAENA (Treatment in Adult Patients, ClinicalTrials.gov Identifier: NCT02386358), 
another randomized trial, assessed the ability of BZN to prevent progression to chronic 
CD in a sample of patients that reflected the natural distribution of the disease (70% 
without demonstrable disease). The trial has recently concluded but results have not yet 
been published. Another ongoing trial, CHICAMOCHA 3, (ClinicalTrials.gov 
Identifier: NCT02369978) is evaluating both BZN and NFX vs. placebo in a sample of 
patients with indeterminate CD. Both safety and parasite clearance will be assessed. 
While BENEFIT, the only major clinical trial of the past decade, showed BZN had 
antiparasitic effect (measured by PCR), it was unable to demonstrate a corresponding 
improvement in clinical outcomes in patients treated with BZN. This likely reflects the 
advanced disease stage of the patients enrolled. In contrast, Viotti et al.’s observational 
study examined patients without advanced cardiomyopathy and included a much longer 
follow-up period (>20 vs. 5.4 years), finding significantly improved clinical outcomes. 
Therefore, the main lesson of the BENEFIT trial is that antiparasitic treatment should be 
offered as early as possible, before patients progress to an advanced stage of CD.[103] 
 
4. Tolerability and Pharmacovigilance 
Adverse Effects 
Treatment discontinuation due to adverse events (AEs) typically ranges from 15-20%. 
AEs are more frequently observed in adolescents and adults than infants and 
children.[7,77,104] Usually, treatment tolerance is satisfactory and patients have not 
demonstrated serious side effects.[7,11,92,104,105] Although cases with severe side 
effects are occasionally reported, these are generally associated with difficulties in 
seeking timely medical attention or receiving adequate care. The most commonly 
reported AEs from BZN include allergic dermopathy, nausea, and vomiting. Cutaneous 
reactions are the most common, and are positively associated with treatment 











bone marrow have been observed. Very rarely, cases with extensive lesions from 
allergic dermopathy, including Steven Johnson Syndrome, have been reported. No new 
AEs have been described in the literature in the past few decades.  
Due to AEs, oral treatments sometimes have to be discontinued. Laboratory tests have 
typically shown normal bilirubin values and occasional elevation of transaminases. In 
all cases, AEs disappear when the dose is diminished or treatment is suspended. 
Children who underwent clinical examination 15 years after experiencing AEs did not 
show any pathological signs or symptoms associated with the adverse events.[108] 
Several studies have attempted to identify predictors of adverse reactions to BZN. Two 
studies concluded that BZN serum concentrations are not correlated with the appearance 
of serious AEs.[109,110] A Colombian study retrospectively evaluated the safety 
profile of BZN in 224 adult patients to identify factors for definitive treatment 
interruption and development of severe reactions.[111] A BZN dose ≥ 6 mg/kg/day, 
adverse event severity, eosinophilia and female sex were the main predictors of 
treatment interruption. 
Differences in patients’ genetic or immunological profile could drive susceptibility to 
AEs. A study of adult CD patients treated with BZN (100 mg, every 8 hours, for 60 
days) showed that patients with cutaneous drug-reactions had a higher proportion of 
eosinophilia during treatment, and higher interleukin (IL)-5 and IL-10 serum 
concentrations at day 15 of treatment than those without cutaneous reactions.[112] 
Treatment interruption (secondary to moderate-severe cutaneous reactions) was more 
frequent in patients carrying the HLA-B*3505 allele (45.5% vs 15.4%, P = 0.033). No 
differences in BZN serum concentrations were found. The authors concluded that the 
BZN cutaneous reaction rate is high (38.5%), and related to a delayed hypersensitivity 
reaction with a Th2-specific immune response. Additionally, the HLA-B*3505 allele 
could be associated with moderate-severe cutaneous reactions. 
 
Clinical Management of Adverse Events 
Despite the toxicological profile and documented side effects of BZN, data from clinical 
studies and the extensive use of the drug in Latin America indicate BZN can be used 











patients had to discontinue treatment secondary to a serious AE, despite the older mean 
age (55) in the sample.[65] In over 2,000 patients treated with BZN by MSF in Bolivia, 
only 10.2% discontinued treatment. MSF used a system of weekly follow-up to 
minimize treatment suspension.[107] 
Treatment of CD with BZN should ideally take place within primary health care 
facilities, which are much more accessible to the patient population. During treatment, 
patients should be continuously monitored. Prior to treatment initiation and biweekly, 
patients should receive a haemogram and tests of renal and hepatic function. Women of 
childbearing age should undergo a pregnancy test before initiation, and use 
contraception during treatment. Management of adverse events depends on their type 
and severity. Strategies for some of the main AEs for benznidazole are suggested in 
recent guidelines,[15] and may involve temporary reduction of daily dose or temporary 
suspension of treatment until AEs resolve. If the patient is near the end of treatment, 
discontinuation may be the best option. According to the Argentinian guidelines, >30 
days is sufficient to consider treatment complete.[16]  
 
Benznidazole during pregnancy and breastfeeding 
BZN is traditionally contraindicated in pregnancy because data that support its safety in 
the fetus are lacking.[113] Nevertheless, when the clinical picture of the patient is 
severe, and given the known lower risks of fetal toxicity in the second and third 
trimesters of pregnancy,[114] treatment has been administered on a compassionate 
basis. There are some case reports in which it was necessary to prescribe treatment with 
BZN during pregnancy due to the risk to the mother’s life in the acute phase after 
vector/oral transmission[115,116] or reactivation of chronic infection for a patient with 
AIDS.[73] All these cases showed a benefit for the mothers with a good response to the 
treatment; no congenital infection was detected in the children born, and no sequelae 
were described in the children during follow-up. 
A prospective study analyzed BZN concentrations in blood samples and breastmilk 
from 12 lactating women receiving treatment for CD.[28] Median observed breastmilk 
BZN concentrations were low; the expected exposure to BZN of breastfeeding infants 











dose, which is considered safe. The researchers concluded mothers’ treatment with BZN 
should not contraindicate breastfeeding in cases where treatment cannot be postponed.  
 
 
5. Regulatory affairs 
Table 3 lists countries where BZN is registered. Most recently (2017), the drug was 
registered in Mexico and the U.S., the countries with the third and sixth highest global 
burdens, respectively. BZN is also on the WHO’s list of essential medicines. The Pan 
American Health Organization, through its strategic fund, purchases BZN and resells it 
to countries where it is not registered. In these countries, the BZN supply is managed by 
ministries of health.  
In the United States, BZN was previously only available through the Centers for 
Disease Control. Physicians were required to submit a special investigational protocol 
in order to receive a supply of BZN for each patient. In 2017, the FDA approved 
registration of benznidazole by Chemo Research (a subsidiary of Insud Pharma). The 
U.S. product is available through a central distributor (for more information see: 
http://www.benznidazoletablets.com/en). 
However, registration alone is insufficient to assure patient access to BZN. Despite the 
proven benefits of etiological treatment of CD, health systems have struggled to make 
the drug available to patients. In the U.S. and other settings, fewer than 1% of expected 
CD cases have received treatment.[19,27,117] While 1,908 cases of CD have been 
identified through testing of U.S. blood donors from 2007-2013, only 422 courses of 
medication were solicited from the CDC, enough to cover just 22% of these cases.[19]  
Several barriers have prevented patients in need from accessing BZN. Both patient and 
provider awareness of CD is low,[18,118] which keeps down the demand for diagnosis. 
Furthermore, many providers still operate under the assumption that CD should not be 
treated in the chronic phase, despite the fact that there is now a consensus in 
international organizations and national guidelines that adults with chronic CD should 
be offered treatment. In addition, CD disproportionately impacts socioeconomically 











In the U.S. and Europe, the majority of CD patients are Latin American immigrants, 
who may be excluded from health insurance coverage or be apprehensive about utilizing 
health services. A recent study indicated that transportation, lack of providers, low 
provider awareness, language barriers, and immigration status were potential barriers 
encountered by U.S. patients with CD.[20] There is no routine screening for CD in the 
U.S. outside of blood and organ donations. Increasing access to BZN will require 
development of broad provider and patient education initiatives, and incorporation of 
treatment into healthcare services which are accessible to the population at risk.   
6. Conclusion 
BZN is a small molecule with a nitroheterocyclic structure that shows broad-spectrum 
trypanocidal activity against T. cruzi strains from different DTUs. It exhibits a time- and 
concentration-dependent effect against intra- and extracellular forms of T. cruzi. Its 
mechanism of action involves activation of the parent molecule by trypanosomal type I 
nitroreductases and generation of reactive metabolites. 
BZN produces a clear trypanocidal effect in humans and plays an essential role in 
primary and secondary prevention. Although treatment with BZN is associated with 
side effects in some patients, it has a good adherence rate and tolerability, especially 
when treatment is carefully monitored. Because of the challenges involved in 
confirming a cure for CD, BZN’s benefit is more readily demonstrated during the acute 
phase, and for children, adolescents, and young adults with chronic indeterminate CD. 
Nonetheless, several observational studies suggest that BZN prevents morbimortality in 
adults. The BENEFIT trial was not able to show a similar effect in a sample of older 
adults who had already developed heart disease from CD. Therefore, every effort should 
be made to identify and treat patients early, before CD progresses to an advanced 
chronic form.  
Another important benefit of BZN treatment is primary prevention. When T. cruzi-
infected women are treated with BZN, congenital transmission is prevented in 
subsequent births. This has tremendous public health importance since congenital 
infection is a major transmission route. Consequently, treatment of women of 
gestational age should be an integral part of public health strategies. Finally, BZN plays 
a critical role in reducing the burden of CD and increasing the number of healthy, 












7. Expert commentary 
Ongoing investigations aim to optimize BZN therapy by adjusting the current standard 
regimen[74,81,84] or by combining BZN with new chemical entities.[81-83] These 
studies are assessing alternatives to improve safety while improving or at least 
maintaining the efficacy of BZN.  
Infants and children respond well to BZN treatment, with relatively few, mostly mild 
adverse events. Treatment early in life produces consistently negative parasitological 
responses on qPCR, even years after treatment, and often causes reversion to negative 
serology. For insight on the role of treatment in prevention of chronic complications 
such as heart disease, studies of treated children with 3 or 4 decades of follow-up will 
be illustrative. The current absence of this type of long-term follow-up data has forced 
researchers to base treatment decisions and recommendations on surrogate markers such 
as antibody titers and parasitological clearance measured by qPCR, which may not have 
adequate sensitivity and specificity. Nevertheless, in paediatric studies, all the surrogate 
markers support BZN’s effectiveness. Additionally, monitoring of treated females who 
bore children later in life has not uncovered a single case of congenital transmission, 
which strongly supports the value of early treatment of CD.  
Public health programs for CD must employ a two-pronged strategy, on the one hand 
interrupting transmission to prevent occurrence of new cases (these measures are cost-
effective), while on the other hand providing timely diagnosis and treatment to infected 
individuals to prevent clinical evolution of the disease, reduce morbidity, and maximize 
healthy years of life. When these actions are implemented in a comprehensive, 
integrated manner, it will be possible to interrupt transmission of T. cruzi in a large 
territory and eliminate CD as a public health problem, with a dramatic reduction in the 
burden of the disease.[14] 
 
8. Five-year view 
Substantial progress has been made in the past decade, improving our understanding of 
BZN’s efficacy and safety. BZN is likely to remain the first-line treatment for CD in the 











insight within the next five years, helping to determine whether intermittent dosage 
schemes, shorter regimens, and/or lower doses are capable of sustaining the efficacy of 
the standard regimen while improving the side effect profile. Moreover, the results of 
the BENDITA trial will indicate whether BZN and E1224 combination therapy can 
yield superior safety and/or efficacy than the standard regimen. Meanwhile, other 
compounds in the nitroheterocyclic class continue to be evaluated. Fexinidazole, 
recently proven effective against human African trypanosomiasis,[119] could be the 
next promising candidate for CD.[120-122]   
Clinical research continues to be hampered by the lack of a reliable measure of cure. 
New biomarkers with improved sensitivity to demonstrate failure and success in a 
timely fashion are needed. Identification of new biomarkers that more accurately 
measure efficacy could revolutionize clinical research and practice, and some initiatives 
are ongoing.[123] 
The 2017 registration of benznidazole in Mexico and the United States removes 
regulatory barriers in two high-burden countries. Nonetheless, much work is needed to 
improve access for patients. Persistently low awareness among providers of current CD 
treatment guidelines, the absence of a gold standard for diagnosis, and a lack of 
widespread screening and treatment at the primary care level are key barriers. Providers 
capable of offering treatment are still too few, and often located too far from areas 
where patients live. Most importantly, CD predominantly impacts socioeconomically 
vulnerable groups who face significant challenges in accessing healthcare; these 
challenges are further magnified for immigrants in Europe and the United States who 
face legal, social, and linguistic barriers. Incorporation of etiological treatment with 
BZN and NFX into the primary health care system is still in its infancy, but successful 
models in Bolivia, Argentina, and elsewhere provide a template other programs can 
follow.[124-126]  
 
9. Key issues 
• BZN is a prodrug that requires activation by trypanosomal type I nitroreductases 
(NTRI). The group of reactive metabolites produced during the activation step is 
toxic, promoting a fast and concentration-dependent kill-off of the parasites. 
• In vitro, BZN has broad-spectrum trypanocidal activity against intra- and 











(DTUs). In several animal models, BZN improves survival, reduces parasite 
load in blood and key reservoir tissues, decreases antibody response to T. cruzi, 
and may prevent the development of severe clinical features of the disease. 
• BZN has a clear trypanocidal effect, which is more evident the more recent the 
infection. Furthermore, there is growing evidence from observational studies 
that etiological treatment with BZN reduces morbimortality when administered 
to adults with chronic CD.  
• Clinical research with new treatment schemes evaluating alternative doses and 
durations as well as combination therapies is ongoing, aiming primarily at 
improving or maintaining efficacy while bolstering safety. 
• There is absolute consensus that treatment with BZN and NFX should be offered 
within primary healthcare. Treatment adherence and safety is greatly enhanced 
when healthcare personnel engage in systematic monitoring of side effects.  
• BZN has been approved in nine countries in the Americas for the treatment of 
CD, including the U.S. and Mexico in August 2017. 
• Etiological treatment with BZN is recommended for acute and congenital cases, 
reactivations in immunocompromised patients, and children in the early chronic 
phase. Treatment should also be offered to adults with chronic infection because 
of evidence that it reduces morbimortality, and is sometimes considered as a 
prophylactic measure in patients about to undergo immunosuppressive therapy. 
Treatment appears to be more effective when administered before the onset of 
serious cardiac complications (Kuschnir class II or III).  
• There is a consensus that patient care involving antitrypanosomal treatment be 
integrated into primary prevention programs, particularly because of its 
demonstrated ability to eliminate congenital transmission. Preventing new cases 
is key to eliminating CD as a public health problem. 
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Table 2. Comparison of studies measuring long-term clinical outcomes after etiological 
treatment of chronic Chagas disease with benznidazole 
First Author Number of treated/ 
untreated patients 
Years of  
follow-up  
% with ECG changes  
treated vs. untreated patients 
% 
t
Viotti 1994 131 / 70 8 4 vs. 30 
Gallerano 2000 535 / 668 5 14 vs. 34 
Viotti 2006 283 / 283 6 5 vs. 16 
Fabbro 2007 54 / 57 21 4 vs. 16 
Fabbro 2014 71 / 46 20 1.4 vs. 15 
Morillo 2015 1431 / 1423 6 − 
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A- Percentage of patients with non-reactive serological test (cure) after treatment. Children 
and adult patients with short- and long-term follow-up. 
 
B- Percentage of patients with positive xenodiagnosis or PCR after treatment. Children and 














Fig 2. A- Percentage of patients with non-reactive serological test (cure) after treatment. 
Children and adult patients with short- and long-term follow-up.
 
Fig 2.B-Figure 2.B- Percentage of patients with positive xenodiagnosis or PCR after 
treatment. Children and adult patients with short- and long-term follow-up. 
